Science & Enterprise subscription

Follow us on Twitter

  • A clinical trial began enrolling participants to collect real world evidence on a digital therapy designed to relie… https://t.co/AMuUt4C0oh
    about 19 mins ago
  • New post on Science and Enterprise: Trial Underway Assessing Insomnia Therapy App https://t.co/qmdNHoo382 #Science #Business
    about 23 mins ago
  • This week's report shows a marked increase in activity on therapies, while the number of vaccines in development an… https://t.co/Z7P2ivWaxJ
    about 8 hours ago
  • New post on Science and Enterprise: Covid-19 Vaccines, Therapies – 13 July 2020 https://t.co/epfuGPmjdy #Science #Business
    about 8 hours ago
  • This is nuts. Manufacturing, distribution, and public health infrastructure here are more important than who made t… https://t.co/AOHVdFBlrX
    about 23 hours ago

Please share Science & Enterprise

Biotech, Diagnostics Companies Partner on Microbe Detection

Petri dishes (USDA.gov)

(USDA.gov)

SDIX, a biotechnology company in Newark, Delaware and BD Diagnostics in Sparks, Maryland have agreed to collaborate on the development of systems to detect microorganisms, in a deal worth as much as $3.75 million. BD Diagnostics is a division of the medical technology company Becton Dickinson and Company in New Jersey.

The goal of the partnership is to commercialize a new system to improve the speed and accuracy of the detection of microorganisms. The companies say SDIX brings expertise in development of antibodies with BD’s background in building diagnostic systems.

One of SDIX’s antibody technologies is based on bacteriophage, more commonly known as phage, which are viruses that infect bacteria with its DNA. The infecting DNA then takes over the replicating mechanisms of the bacteria. SDIX has a patent on this technology.

SDIX will provide BD Diagnostics access to its antibody technology and a non-exclusive license to its bacteriophage technology. BD will pay SDIX a $1.25 million upfront fee. In addition, the agreement provides for up to $2.5 million in milestone payments and royalties on sales of products with SDIX’s technology. Once this system is on the market, SDIX and BD plan to have a long term agreement for the supply of antibodies from SDIX to BD.

Read more: Genomic Sequencing Precisely Targets Food Pathogens

*     *     *

Please share Science & Enterprise ...

Comments are closed.